Background/Aims: In Japan, a systematic eradication strategy for Helicobacter pylori has been constructed, and consists of a proton pump inhibitor/amoxicillin and clarithromycin (PPI/AC) therapy as the first-line regimen and proton pump inhibitor/amoxicillin and metronidazole (PPI/AM) therapy as the second-line regimen. The cumulative rate of H. pylori eradication has not been reported. Therefore, we investigated the annual and cumulative eradication rate to verify the efficacy of the ‘Japanese eradication strategy'. Methods: Patients who received first-line PPI/AC therapy and, if necessary, second-line PPI/AM therapy between 2000 and 2009 were retrospectively analyzed. The annual cumulative eradication rate was calculated. Data were subjected to intention-to-treat analysis. Results: PPI/AC was administered to 1973 patients (male n = 1,162, female n = 811; mean age: 55.8 years, range: 15-87), and 250 patients received PPI/AM. The eradication rate for the PPI/AC regimen was 65.3%, and it gradually but significantly decreased over 10 years (p < 0.05). For the PPI/AM regimen, the eradication rate was 84.0%, with no change in the annual eradication rate. The cumulative eradication rates were 76.0% in intention-to-treat analysis and 98.4% in per-protocol analysis, respectively, which provided a consistent annual eradication rate without decreases in effectiveness. Conclusion: Although the eradication rate for the first-line PPI/AC regimen decreased over time, the ‘Japanese eradication strategy' provided a sufficient eradication rate.

1.
Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K: Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
[PubMed]
2.
Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825.
[PubMed]
3.
Sasaki M, Ogasawara N, Utumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T: Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 2010;47:53-58.
[PubMed]
4.
Sugizaki K, Sakata Y, Arai T, Furuhata Y, Iinuma N, Suzuki H: A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan. Intern Med 2012;51:3103-3108.
[PubMed]
5.
Gisbert JP, McNicholl AG: Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter 2012;17:160-161.
[PubMed]
6.
Gisbert JP, Calvet X: Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-1268.
[PubMed]
7.
Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, Gottrand F, Celinska-Cedro D, Roma-Giannikou E, Orderda G, Kolacek S, Urruzuno P, Martínez-Gómez MJ, Casswall T, Ashorn M, Bodanszky H, Mégraud F: Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006;55:1711-1716.
[PubMed]
8.
Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y: Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009;14:86-90.
[PubMed]
9.
Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, Nasu M, Fujioka T: Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-4010.
[PubMed]
10.
Miwa H, Nagahara A, Kurosawa A, Ohkusa T, Ohkura R, Hojo M, Enomoto N, Sato N: Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003;17:1545-1551.
[PubMed]
11.
Roccarina D, Franceschi F, Zocco MA, Garcovich M, Gasbarrini G, Gasbarrini A: Different antibiotic no culture eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis 2012;44:889-892.
[PubMed]
12.
Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T: Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J Clin Gastroenterol 2008;42:139-142.
[PubMed]
13.
Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J: Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17:119-123.
[PubMed]
14.
Graham DY, Lu H, Yamaoka Y: A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-278.
[PubMed]
15.
Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D: Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-25.
[PubMed]
16.
Nagahara A, Miwa H, Ogawa K, Kurosawa A, Ohkura R, Iida N, Sato N: Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000;5:88-93.
[PubMed]
17.
Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N: Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:417-421.
[PubMed]
18.
Stranz MH, Bradley WE: Metronidazole (Flagyl IV, Searle). Drug Intell Clin Pharm 1981;15:838-846.
[PubMed]
19.
Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanabe S, Sato N: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999;13:741-746.
[PubMed]
20.
Furuta T, Shirai N, Ohashi K, Ishizaki T: Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol 2003;25:131-143.
[PubMed]
21.
Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001;15:793-803.
[PubMed]
22.
Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G: Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol 2002;26:216-219.
[PubMed]
23.
Nagahara A, Miwa H, Hojo M, Yoshizawa T, Kawabe M, Osada T, Kurosawa A, Ohkusa T, Watanabe S: Efficacy of Lansap combination therapy for eradication of H. pylori. Helicobacter 2007;12:643-644.
[PubMed]
You do not currently have access to this content.